Iconovo

Iconovo is a specialized inhalation drug delivery company offering end-to-end development of inhaled therapies. Its core business model combines a portfolio of patented dry powder inhaler platforms with integrated formulation expertise to partner with pharma companies. A key strategic aim is to leverage the patent cliff for biologics by developing inhaled alternatives to injections, exemplified by its pipeline project for inhaled semaglutide. The company is publicly traded and recently secured capital through directed and rights issues to fund its development programs.

Integrated development of patented dry powder inhaler devices and tailored powder formulations for inhalation drug delivery, with a focus on systemic delivery of biologics.

Iconovo competes with large medical device companies (e.g., 3M, Aptar) offering standard DPI platforms, as well as other specialized inhalation CDMOs and biotechs. Its differentiation lies in its deep, integrated formulation expertise specifically for dry powder and its strategic focus on systemic delivery of complex molecules like peptides and proteins.